Named on one round in the feed.
Since 2025-05-27
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
GlycoEra Biologics aimed at precision immunology, targeting and degrading specific proteins associated with autoimmune diseases for improved patient outcomes. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $130M | 2025-05-27 | [ PART ] |
No sector on record.